The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 26, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 26.
Number 5: The US Patent Trial and Appeal Board has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review of Allergan’s patents covering Restasis, and that the proceedings can continue with Allergan as the patent owner.
Number 4: Infliximab has been proposed as a potential combination treatment that could enhance the effects of chemotherapy in patients with colon cancer.
Number 3: The American College of Rheumatology has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
Number 2: Virginia’s House and Senate have passed a new bill that prohibits pharmacy benefit managers from penalizing pharmacists for sharing drug price information with customers.
Number 1: A health economist from Harvard Medical School is warning that, if biosimilars continue their current trajectory, they could fail to deliver on their promise to provide cost savings to the US health system.
Finally, last week, our e-newsletter asked for your thoughts on whether the extrapolation of indications for biosimilars is reasonable.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.